In this free webinar, learn how dry eye disease ophthalmic trials are embracing new technologies to accelerate programs and gain better insights into product efficacy. Attendees will learn about smart protocol design and endpoint selection when conducting hybrid/decentralized trials. The featured speakers will discuss the tools for dry eye disease trial administration and improved endpoints. The speakers will also discuss the right way to balance new technologies and approaches with traditional practices to ensure protocol compliance and data integrity.
TORONTO, Sept. 22, 2022 /PRNewswire-PRWeb/ -- The quintessential post-menopausal female dry eye disease patient has now become entirely obsolete. Dry eye disease is an extremely prevalent ocular condition worldwide and with both environmental and genetic factors playing a role, affecting people of all ages and genders.
While clinical trials in dry eye disease have been conducted for decades, significant advancements over the past several years have created new approaches to standardize processes, harmonize systems and speed up successful trial completion. In the past, treatments for dry eye disease have solely focused on replenishing tears, but with further understanding of various etiologies of this condition, a polypharmacy approach can be taken to manage this multifactorial disease. The COVID-19 pandemic has accelerated innovation in telehealth, hybrid healthcare partnering in-person visits with online tools and new technologies with at-home patient data capture capabilities.
Equally exciting is the news that this evolution in healthcare is now making its way to clinical trials. New tools, technologies and regulatory changes are leading to significant shifts in trial design and execution. Various innovative methods and devices are being utilized to standardize clinical trial processes, reduce variability and increase the likelihood of success for drug development. Hybrid or decentralized approaches are opening access to a more diverse patient population, while new technologies generate endpoints that strengthen environmental studies and better assess therapeutic impact on quality of life, all while reducing the burden on sites and impact on budgets of pharmaceutical and medical device companies.
Register to hear the featured speakers discuss how dry eye disease ophthalmic trials are embracing new technologies to accelerate programs and gain better insights into product efficacy.
Join experts from Ora, George W. Ousler III, Senior Vice President, Anterior Segment; Dr. Ethan Bensinger, PhD, Clinical Scientist; and Maurice Marquis, R&D Systems Engineer, for the live webinar on Wednesday, October 12, 2022, at 11am EST (4pm BST/UK).
For more information, or to register for this event, visit Trials of Tomorrow: The Latest Technologies Advancing Dry Eye Disease Research.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Advertisement
TORONTO, Sept. 22, 2022 /PRNewswire-PRWeb/ -- The quintessential post-menopausal female dry eye disease patient has now become entirely obsolete. Dry eye disease is an extremely prevalent ocular condition worldwide and with both environmental and genetic factors playing a role, affecting people of all ages and genders.
Advertisement
While clinical trials in dry eye disease have been conducted for decades, significant advancements over the past several years have created new approaches to standardize processes, harmonize systems and speed up successful trial completion. In the past, treatments for dry eye disease have solely focused on replenishing tears, but with further understanding of various etiologies of this condition, a polypharmacy approach can be taken to manage this multifactorial disease. The COVID-19 pandemic has accelerated innovation in telehealth, hybrid healthcare partnering in-person visits with online tools and new technologies with at-home patient data capture capabilities.
Equally exciting is the news that this evolution in healthcare is now making its way to clinical trials. New tools, technologies and regulatory changes are leading to significant shifts in trial design and execution. Various innovative methods and devices are being utilized to standardize clinical trial processes, reduce variability and increase the likelihood of success for drug development. Hybrid or decentralized approaches are opening access to a more diverse patient population, while new technologies generate endpoints that strengthen environmental studies and better assess therapeutic impact on quality of life, all while reducing the burden on sites and impact on budgets of pharmaceutical and medical device companies.
Register to hear the featured speakers discuss how dry eye disease ophthalmic trials are embracing new technologies to accelerate programs and gain better insights into product efficacy.
Join experts from Ora, George W. Ousler III, Senior Vice President, Anterior Segment; Dr. Ethan Bensinger, PhD, Clinical Scientist; and Maurice Marquis, R&D Systems Engineer, for the live webinar on Wednesday, October 12, 2022, at 11am EST (4pm BST/UK).
For more information, or to register for this event, visit Trials of Tomorrow: The Latest Technologies Advancing Dry Eye Disease Research.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
